The buying signal from two executives is mildly positive but too small in magnitude to suggest strong conviction; monitor for follow-up purchases or larger capital commitments.
GENB drugs
GENB drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 3 $11.93entry
- T+1 · 9mo ago −2.93%α −3.64% · $11.58
- T+5 · 8mo ago +2.35%α +2.81% · $12.21
- T+20 · 8mo ago +4.78%α +9.19% · $12.50
- T+60 · 6mo ago +9.72%α −1.19% · $13.09
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A cluster of insider transactions at Generate Biomedicines (GENB) over the past week includes two open-market purchases totaling $32,000 by executives Mendillo Jane L and Silvers Jason, alongside multiple non-cash derivative conversions by insiders including CEO Michael Nally and others. The purchases are small in absolute value and represent minimal economic activity relative to the company's market cap.
Key Financial Metrics
Key Facts
- Two open-market purchases occurred: Mendillo Jane L bought 1,500 shares ($24,000) and Silvers Jason (President & CFO) bought 500 shares ($8,000).
- Multiple non-cash derivative conversions totaling over 26 million shares were executed at $0 value, including by CEO Michael Nally and Stephane Bancel.
- Total open-market buying: $32,000 over 7 days, consistent with recent 30-day activity.
- No open-market selling occurred in the cluster.
Financial Impact
$32,000 in open-market purchases, representing a negligible fraction of market cap (<0.01%)
Risk Factors
- Non-cash transactions (conversions) dominate the cluster and do not reflect actual buying or selling activity.
- Small purchase size limits predictive value for stock performance.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (6 trades, 7d window) | cluster-GENB-1772492108578 |
Track record
11 reports on GENB
5 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +14.28% at T+20 after the Oct 1, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 5/10 Entry $12.57 Now $10.49 +16.55% settles Dec 11
- Nov 5, 202611d ago SC 13G Neutral 3/10 Entry $12.57 Now $10.49 −16.55% settles Dec 4
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $13.85 Now $10.49 −24.26% settles Dec 2
- Oct 29, 202618d ago 144 Neutral 2/10 Entry $14.46 Now $10.49 −27.46% settles Nov 30
- Oct 13, 20264w ago Press Release Bullish 6/10 Entry $12.52 to $13.49 Now $10.49 −16.21% ▲ +7.75% +9.02% vs SPY
- Oct 1, 20266w ago Press Release Bullish 5/10 Entry $13.80 to $15.77 Now $10.49 −23.99% ▲ +14.28% +13.57% vs SPY
- May 7, 202627w ago 8-K Bearish 6/10 Entry $13.59 to $12.91 Now $10.49 +22.81% ▲ +5.00% +8.14% vs SPY
- Mar 2, 202637w ago Insider Cluster Bullish 7/10 Entry $11.93 to $12.50 Now $10.49 −12.07% ▲ +4.78% +9.19% vs SPY
- Mar 2, 202637w ago Insider Cluster Neutral 3/10 Viewing Entry $11.93 to $12.50 Now $10.49 −12.07% ▲ +4.78% +9.19% vs SPY
- Feb 27, 202637w ago 424B4 Bearish 7/10 Entry $12.17 to $11.51 Now $10.49 +13.80% ▲ +5.42% −2.52% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers